Mylan Pharmaceutical has issued a voluntary recall for three more blood pressure medications over possible cancer concerns.
The recalled drugs all include the medication valsartan, which has been the subject of recalls by several companies since July.
According to the drug maker, testing revealed the medication contains trace amounts of NDEA, a possible human carcinogen.